21 completed, 9 active not recruiting, 9 recruiting, 9 unknown. 32 Phase 2, 21 Phase 1, 5 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow Classical Hodgkin Lymphoma: new trials by email Literature Review of Classical Hodgkin Lymphoma trials Research Report on Classical Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma CD30 CAR T-cell - Classical Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | New York Medical College | 21 | 2026-12-01 | 2026-04-15 |
| CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma CD30+ CAR T-cells, Bendamustin, Fludarabine - Classical Hodgkin Lymphoma | Phase 1 | Not yet recruiting | New York Medical College | 12 | 2026-10-01 | 2026-05-20 |
| European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma Classical Hodgkin Lymphoma | Recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2025-11-24 | 2026-01-21 | |
| Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma Pembrolizumab - Classical Hodgkin Lymphoma | Phase 2 | Not yet recruiting | University of Cologne | 50 | 2025-06-01 | 2025-04-08 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study Sintilimab in combination with AVD chemotherapy - Classical Hodgkin Lymphoma | Phase 2 | Recruiting | Sun Yat-sen University | 73 | 2024-10-23 | 2025-02-27 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Tislelizumab - Classical Hodgkin Lymphoma | Phase 2 | Recruiting | University of Cologne | 120 | 2024-05-24 | 2024-07-26 |
| Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma Pembrolizumab plus Chemotherapy (ICE or DHAP) - Classical Hodgkin Lymphoma | Phase 2 | Recruiting | University of Cologne | 29 | 2024-03-05 | 2024-08-23 |
| Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas CD30.CAR-EBVST cells - Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma | Phase 1 | Withdrawn | Baylor College of Medicine | 2024-03-01 | 2023-09-07 | |
| Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors Lifestyles Implemented-Survivorship Care Plan (LS-SCP) - Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Not applicable | Recruiting | Fondazione Italiana Linfomi - ETS | 552 | 2024-02-26 | 2026-09-11 |
| Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents Classical Hodgkin Lymphoma | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 36 | 2024-02-07 | 2025-02-07 | |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma GEN3017 - Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 9 | 2023-09-21 | 2025-09-25 |
| A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma Zimberelimab 240mg - Classical Hodgkin Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 54 | 2023-06-14 | 2023-06-18 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Active not recruiting | University of Virginia | 24 | 2022-07-26 | 2026-05-14 |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Nivolumab, Autologous CD30.CAR-T, Fludarabine - Classical Hodgkin Lymphoma, Hodgkin Disease Refractory | Phase 1 | Active not recruiting | Tessa Therapeutics | 15 | 2022-07-25 | 2023-04-03 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent | Recruiting | Azienda USL Reggio Emilia - IRCCS | 755 | 2022-06-23 | 2026-05-29 | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Pembrolizumab, Bendamustine Hydrochloride - Classical Hodgkin Lymphoma, Relapsed Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2021-12-20 | 2026-06-23 |
Showing 20 of 60. Sign in to see all of them.
Hodgkin Disease (14) · Melanoma (8) · Carcinoma, Non-Small-Cell Lung (7) · Lymphoma, Non-Hodgkin (5) · Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinoma, Transitional Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Squamous Cell Carcinoma of Head and Neck (4) · Lymphoma, T-Cell, Peripheral (3) · Stomach Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Merkel Cell (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2)
Neoplasms by Histologic Type (27) · Neoplasms (25) · Hemic and Lymphatic Diseases (23) · Lymphatic Diseases (23) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Lymphoproliferative Disorders (22) · Lymphoma (20) · Neoplasms by Site (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Nerve Tissue (8) · Neuroectodermal Tumors (8) · Neuroendocrine Tumors (8)
pembrolizumab (13) · Dacarbazine (10) · Doxorubicin (10) · Brentuximab Vedotin (8) · Vinblastine (7) · Nivolumab (6) · Bendamustine Hydrochloride (5) · Cyclophosphamide (5) · Prednisone (5) · tislelizumab (5) · Etoposide (4) · Vincristine (4) · Bleomycin (3) · Gemcitabine (2) · Procarbazine (2)
University of Cologne (7) · BeiGene (3) · Sun Yat-sen University (3) · Baylor College of Medicine (2) · Fondazione Italiana Linfomi - ETS (2) · Merck Sharp & Dohme LLC (2) · New York Medical College (2) · Assistance Publique - Hôpitaux de Paris (1) · Azienda USL Reggio Emilia - IRCCS (1) · Barbara Ann Karmanos Cancer Institute (1) · Centre Henri Becquerel (1) · Checkpoint Therapeutics, Inc. (1) · Children's Cancer Group, China (1) · Emory University (1) · Genmab (1)
United States (23) · China (10) · Italy (9) · France (8) · Germany (8) · Spain (6) · Australia (5) · United Kingdom (5) · Israel (4) · Canada (3) · Poland (3) · Belgium (2) · New Zealand (2) · Russia (2) · South Korea (2)
Andreas Engert, Prof. (3) · Helen Heslop, MD (2) · Andrea Soricelli, Prof (1) · Andres Forero-Torres, MD (1) · Ayman Hejazi, MD (1) · Carla Minoia, MD (1) · Carlos Ramos, MD (1) · Christof Scheid, Prof. (1) · Dennis Eichenauer, Dr. (1) · Dieter Koerholz, MD (1) · Dipenkumar Modi, M.D. (1) · Elena Sabattini, MD (1) · Erlinda M Gordon, MD (1)
PMID 40135712, PMID 24089446, PMID 31401903, PMID 31508518, PMID 31520078, PMID 31812554, PMID 32079702, PMID 32352505, PMID 32992341, PMID 33332484, PMID 34520052, PMID 34716199, PMID 35332334, PMID 35973200, PMID 36083129, PMID 36200380, PMID 36508302, PMID 36779325, PMID 36913694, PMID 37848259, PMID 37979133, PMID 38971175, PMID 39058968, PMID 40624058, PMID 40652943, PMID 40674676, PMID 41926569, PMID 42379221
2014 (3), 2019 (2), 2018 (1), 2023 (1), P30CA022453 (1), P30CA060553 (1), P30CA138292 (1)